Loading clinical trials...

Probability of Target Attainment With Standard Intermittent Bolus Administration of Cefazolin in Patients With Complicated Infections Caused by Staphylococcus Aureus | Clinical Trials | Clareo Health

COMPLETED

Probability of Target Attainment With Standard Intermittent Bolus Administration of Cefazolin in Patients With Complicated Infections Caused by Staphylococcus Aureus

Probability of Target Attainment With Standard Intermittent Bolus Administration of Cefazolin in Patients With Complicated Infections Caused by Staphylococcus Aureus: A Prospective Single-center Cohort Study

NCT04503252•University Hospital, Basel, Switzerland

View on ClinicalTrials.gov

Summary

Given the paucity of pharmacological data on cefazolin treatment of Methicillin-susceptible S. aureus (MSSA) complicated S. aureus infection (CSAI), the primary purpose of this study is to investigate the probability of pharmacological target attainment (in the blood and infected tissue) with standard intermittent bolus administration of cefazolin in patients with CSAI caused by MSSA by determining plasma concentrations of cefazolin and exact Minimum inhibitory concentration (MICs) of the causative MSSA strains in patients with various disease severities (e.g. critically ill vs. noncritically ill patients). * Sub-study quantitative measurement of Torque Teno virus (TTV): The primary purpose of this sub-study is to describe the viral kinetics of TTV in CSAI patients and to explore the association of TTV viremia with clinical outcomes and molecular markers of activation of the immune system. * Sub-study investigating antibiotic concentrations in sweat as a non-invasive therapeutic drug monitoring

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•CSAI caused by MSSA. CSAI is defined as MSSA BSI with a positive follow-up blood culture result for MSSA or the presence of a site of infection remote from the primary focus caused by hematogenous seeding (e.g. endocarditis, vertebral osteomyelitis) or extension of the infection beyond the primary focus (e.g. septic thrombophlebitis or abscess); or deep-seated infections caused by MSSA (e.g. osteoarticular infections, deepseated abscesses).
•Current or intended treatment with cefazolin

Exclusion Criteria

•Previous enrolment into the current study within 30 days
•Hemodialysis (patients on hemofiltration are eligible)
•Patients who are very likely to stop treatment with cefazolin in the next 48 hours as per treating physician (because of treatment failure, switch to oral medication, palliative care, allergy etc.) or who are very likely to be discharged in the next 48 hours as per treating physician.
•Outpatients
•Women who are pregnant (special pharmacokinetic)
•Polymicrobial infection except concomitant isolation of a likely contaminant (e.g. Staphylococcus epidermidis or Propionibacterium acnes) or an anaerobic pathogen. If an additional pathogen is identified after inclusion of the patient into the study, the patient will remain in the study.
•Not-complicated S. aureus infections: non-bacteremic skin- and soft tissue or small Joint infections without deep-seated abscesses (as these patients will be quickly switched to oral antibiotics)
•CSAI caused by methicillin-resistant S. aureus (MRSA)
•Allergic to pilocarpine
•Continuous oxygen therapy without the possibility to interrupt oxygen administration for 10min
+1 more criteria

Locations (1)

University Hospital Basel, Division of Internal Medicine

Basel, Switzerland

Key Dates

Start Date

January 14, 2020

Primary Completion Date

March 28, 2022

Completion Date

March 28, 2022

Last Updated

March 29, 2022

Enrollment

ACTUAL participants

Conditions

Staphylococcus Aureus Infection

Interventions

Blood samples for the measurement of the concentration of cefazolin

OTHER

S. aureus culture isolate

OTHER

structured telephone interview

OTHER

Sub-study quantitative measurement of Torque Teno virus

OTHER

Sub-study investigating cefazolin concentrations in sweat

OTHER

Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial

NCT05899140

Skin InfectionStaphylococcal Infections+1 more

View study

RECRUITINGPHASE1/PHASE2

Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®

NCT06319235

Surgical Site InfectionStaphylococcus Aureus Infection+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 29, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Probability of Target Attainment With Standard Intermittent Bolus Administration of Cefazolin in Patients With Complicated Infections Caused by Staphylococcus Aureus

Inclusion Criteria

Exclusion Criteria

Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial

Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®

Immune Resolution After Staphylococcus Aureus Bacteremia

Safety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung Infections

Antistaphylococcal Betalactam and Emergence of Resistance

Livestock Contact and MRSA in Rural Areas